AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB

AlphaQuest LLC decreased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 96.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 375 shares of the biotechnology company’s stock after selling 10,789 shares during the quarter. AlphaQuest LLC’s holdings in Biogen were worth $53,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BIIB. Elevation Point Wealth Partners LLC acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $25,000. Rothschild Investment LLC lifted its stake in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the last quarter. True Wealth Design LLC lifted its stake in Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the last quarter. NewSquare Capital LLC boosted its holdings in shares of Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares in the last quarter. Finally, WFA of San Diego LLC bought a new position in shares of Biogen in the 2nd quarter valued at $32,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIIB has been the subject of several recent analyst reports. Piper Sandler upped their price objective on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Canaccord Genuity Group boosted their target price on Biogen from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. HSBC reissued a “reduce” rating and issued a $143.00 target price (down previously from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Robert W. Baird decreased their price target on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Finally, Wells Fargo & Company upped their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Twelve investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $205.84.

Biogen Stock Performance

NASDAQ BIIB opened at $196.52 on Monday. The company has a market capitalization of $28.84 billion, a price-to-earnings ratio of 22.31, a PEG ratio of 1.56 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The stock has a fifty day simple moving average of $178.22 and a 200 day simple moving average of $159.29.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is owned by insiders.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.